1.40Open1.30Pre Close10 Volume24 Open Interest12.50Strike Price1.40KTurnover338.96%IV48.87%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry1.40Extrinsic Value100Contract SizeAmericanOptions Type-0.1402Delta0.0122Gamma10.72Leverage Ratio-0.0905Theta-0.0029Rho-1.50Eff Leverage0.0120Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet